Source:
CBS News/APAvandia, the biggest-selling diabetes drug in the world, is linked to a greater risk of heart attack and possibly death, says a new scientific analysis published online Monday.
More than 6 million people worldwide have taken the drug sold by London-based GlaxoSmithKline PLC since it came on the market eight years ago. Pooled results of dozens of studies revealed a 43 percent higher risk of heart attack, according to the review published by the New England Journal of Medicine.
Experts said the overall risk was small and cautioned people not to stop taking the drug on their own but to talk to their doctors.
The company downplayed the report of heart risks, saying the analysis by Dr. Steven Nissen and statistician Kathy Wolski at the Cleveland Clinic is not definitive scientific proof. In a conference call Monday, Dr. Lawson McCartney, who leads Glaxo's diabetes drug development, said the company is not seeing "anything like" the problems reported in the medical journal.
Read more:
http://www.cbsnews.com/stories/2007/05/21/health/main2831501.shtml